Targeting P2 receptors—current progress in treating musculoskeletal diseases
Highlights • Various P2 receptor knockout mice have alterations in the musculoskeletal system. • P2X receptor signalling is a novel target for cancer-induced bone pain. • P2X7 receptor agonists have pharmaceutical potential in treating osteoporosis. • ADP acts as a powerful osteolytic agent via P2Y1...
Gespeichert in:
| Veröffentlicht in: | Current opinion in pharmacology 2014-06, Vol.16, p.122-126 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 126 |
|---|---|
| container_issue | |
| container_start_page | 122 |
| container_title | Current opinion in pharmacology |
| container_volume | 16 |
| creator | Wang, Ning Gartland, Alison |
| description | Highlights • Various P2 receptor knockout mice have alterations in the musculoskeletal system. • P2X receptor signalling is a novel target for cancer-induced bone pain. • P2X7 receptor agonists have pharmaceutical potential in treating osteoporosis. • ADP acts as a powerful osteolytic agent via P2Y13 signalling. • The P2Y12 receptor antagonist Clopidogrel is associated with osteoporotic fracture. |
| doi_str_mv | 10.1016/j.coph.2014.05.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1550075717</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1471489214000459</els_id><sourcerecordid>1550075717</sourcerecordid><originalsourceid>FETCH-LOGICAL-c521t-edd8ba57a12e309bc33522115c96e33f0483ac88a97d84d14fbf4a1b53ab9f1c3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhiMEohd4ARYoSzYnzPhSOxJCQhVQpAoqUdaW40wOPs1JDp6kUnd9CJ6QJ6nDabtgwcqz-P5f42-K4hVChYAnbzdVGHc_KwGoKtAVgHpSHKIyuFK1kU8fZluLg-KIeQOAWkrzvDgQylowYA-Lr5c-rWmKw7q8EGWiQLtpTPzn9neYU6JhKndpXCdiLuNQTon8X3Y7c5j7ka-op8n3ZRuZPBO_KJ51vmd6ef8eFz8-fbw8PVudf_v85fTD-SpogdOK2tY2XhuPgiTUTZBSC4GoQ31CUnagrPTBWl-b1qoWVdd0ymOjpW_qDoM8Lt7se_N2v2biyW0jB-p7P9A4s0OtAYw2aDIq9mhII3Oizu1S3Pp04xDc4tFt3OLRLR4daJc95tDr-_652VL7GHkQl4F3e4DyL68jJcch0hCojVni5Nox_r___T_x0MchBt9f0Q3xZpzTkP05dCwcuO_LJZdDooIc17W8Aw6hmt8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1550075717</pqid></control><display><type>article</type><title>Targeting P2 receptors—current progress in treating musculoskeletal diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wang, Ning ; Gartland, Alison</creator><creatorcontrib>Wang, Ning ; Gartland, Alison</creatorcontrib><description>Highlights • Various P2 receptor knockout mice have alterations in the musculoskeletal system. • P2X receptor signalling is a novel target for cancer-induced bone pain. • P2X7 receptor agonists have pharmaceutical potential in treating osteoporosis. • ADP acts as a powerful osteolytic agent via P2Y13 signalling. • The P2Y12 receptor antagonist Clopidogrel is associated with osteoporotic fracture.</description><identifier>ISSN: 1471-4892</identifier><identifier>EISSN: 1471-4973</identifier><identifier>DOI: 10.1016/j.coph.2014.05.004</identifier><identifier>PMID: 24880708</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Animals ; Bone and Bones - metabolism ; Cartilage - metabolism ; Humans ; Internal Medicine ; Medical Education ; Musculoskeletal Diseases - metabolism ; Neoplasms - metabolism ; Receptors, Purinergic P2 - metabolism</subject><ispartof>Current opinion in pharmacology, 2014-06, Vol.16, p.122-126</ispartof><rights>Elsevier Ltd</rights><rights>2014 Elsevier Ltd</rights><rights>Copyright © 2014 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c521t-edd8ba57a12e309bc33522115c96e33f0483ac88a97d84d14fbf4a1b53ab9f1c3</citedby><cites>FETCH-LOGICAL-c521t-edd8ba57a12e309bc33522115c96e33f0483ac88a97d84d14fbf4a1b53ab9f1c3</cites><orcidid>0000-0002-2663-7515 ; 0000-0002-3712-2437</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1471489214000459$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24880708$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Gartland, Alison</creatorcontrib><title>Targeting P2 receptors—current progress in treating musculoskeletal diseases</title><title>Current opinion in pharmacology</title><addtitle>Curr Opin Pharmacol</addtitle><description>Highlights • Various P2 receptor knockout mice have alterations in the musculoskeletal system. • P2X receptor signalling is a novel target for cancer-induced bone pain. • P2X7 receptor agonists have pharmaceutical potential in treating osteoporosis. • ADP acts as a powerful osteolytic agent via P2Y13 signalling. • The P2Y12 receptor antagonist Clopidogrel is associated with osteoporotic fracture.</description><subject>Animals</subject><subject>Bone and Bones - metabolism</subject><subject>Cartilage - metabolism</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical Education</subject><subject>Musculoskeletal Diseases - metabolism</subject><subject>Neoplasms - metabolism</subject><subject>Receptors, Purinergic P2 - metabolism</subject><issn>1471-4892</issn><issn>1471-4973</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1TAQhiMEohd4ARYoSzYnzPhSOxJCQhVQpAoqUdaW40wOPs1JDp6kUnd9CJ6QJ6nDabtgwcqz-P5f42-K4hVChYAnbzdVGHc_KwGoKtAVgHpSHKIyuFK1kU8fZluLg-KIeQOAWkrzvDgQylowYA-Lr5c-rWmKw7q8EGWiQLtpTPzn9neYU6JhKndpXCdiLuNQTon8X3Y7c5j7ka-op8n3ZRuZPBO_KJ51vmd6ef8eFz8-fbw8PVudf_v85fTD-SpogdOK2tY2XhuPgiTUTZBSC4GoQ31CUnagrPTBWl-b1qoWVdd0ymOjpW_qDoM8Lt7se_N2v2biyW0jB-p7P9A4s0OtAYw2aDIq9mhII3Oizu1S3Pp04xDc4tFt3OLRLR4daJc95tDr-_652VL7GHkQl4F3e4DyL68jJcch0hCojVni5Nox_r___T_x0MchBt9f0Q3xZpzTkP05dCwcuO_LJZdDooIc17W8Aw6hmt8</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Wang, Ning</creator><creator>Gartland, Alison</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2663-7515</orcidid><orcidid>https://orcid.org/0000-0002-3712-2437</orcidid></search><sort><creationdate>20140601</creationdate><title>Targeting P2 receptors—current progress in treating musculoskeletal diseases</title><author>Wang, Ning ; Gartland, Alison</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c521t-edd8ba57a12e309bc33522115c96e33f0483ac88a97d84d14fbf4a1b53ab9f1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Bone and Bones - metabolism</topic><topic>Cartilage - metabolism</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical Education</topic><topic>Musculoskeletal Diseases - metabolism</topic><topic>Neoplasms - metabolism</topic><topic>Receptors, Purinergic P2 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Ning</creatorcontrib><creatorcontrib>Gartland, Alison</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current opinion in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Ning</au><au>Gartland, Alison</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting P2 receptors—current progress in treating musculoskeletal diseases</atitle><jtitle>Current opinion in pharmacology</jtitle><addtitle>Curr Opin Pharmacol</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>16</volume><spage>122</spage><epage>126</epage><pages>122-126</pages><issn>1471-4892</issn><eissn>1471-4973</eissn><abstract>Highlights • Various P2 receptor knockout mice have alterations in the musculoskeletal system. • P2X receptor signalling is a novel target for cancer-induced bone pain. • P2X7 receptor agonists have pharmaceutical potential in treating osteoporosis. • ADP acts as a powerful osteolytic agent via P2Y13 signalling. • The P2Y12 receptor antagonist Clopidogrel is associated with osteoporotic fracture.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>24880708</pmid><doi>10.1016/j.coph.2014.05.004</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-2663-7515</orcidid><orcidid>https://orcid.org/0000-0002-3712-2437</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-4892 |
| ispartof | Current opinion in pharmacology, 2014-06, Vol.16, p.122-126 |
| issn | 1471-4892 1471-4973 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1550075717 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Animals Bone and Bones - metabolism Cartilage - metabolism Humans Internal Medicine Medical Education Musculoskeletal Diseases - metabolism Neoplasms - metabolism Receptors, Purinergic P2 - metabolism |
| title | Targeting P2 receptors—current progress in treating musculoskeletal diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T03%3A28%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20P2%20receptors%E2%80%94current%20progress%20in%20treating%20musculoskeletal%20diseases&rft.jtitle=Current%20opinion%20in%20pharmacology&rft.au=Wang,%20Ning&rft.date=2014-06-01&rft.volume=16&rft.spage=122&rft.epage=126&rft.pages=122-126&rft.issn=1471-4892&rft.eissn=1471-4973&rft_id=info:doi/10.1016/j.coph.2014.05.004&rft_dat=%3Cproquest_cross%3E1550075717%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1550075717&rft_id=info:pmid/24880708&rft_els_id=1_s2_0_S1471489214000459&rfr_iscdi=true |